RA Capital Management’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,365,523
| Closed | -$743M | – | 88 |
|
|
2025
Q4 | $743M | Hold |
3,365,523
| – | – | 7.62% | 2 |
|
|
2025
Q3 | $322M | Hold |
3,365,523
| – | – | 3.97% | 5 |
|
|
2025
Q2 | $164M | Buy |
3,365,523
+2,272,727
| +208% | +$54.6M | 2.76% | 11 |
|
|
2025
Q1 | $23.5M | Hold |
1,092,796
| – | – | 0.39% | 37 |
|
|
2024
Q4 | $29.4M | Buy |
1,092,796
+389,716
| +55% | +$6.33M | 0.39% | 45 |
|
|
2024
Q3 | $7.56M | Buy |
+703,080
| New | +$8.44M | 0.09% | 71 |
|
|
2016
Q3 | – | Sell |
-20,540
| Closed | -$4.24M | – | 31 |
|
|
2016
Q2 | $4.24M | Sell |
20,540
-38,171
| -65% | -$9.24M | 0.59% | 26 |
|
|
2016
Q1 | $14.9M | Hold |
58,711
| – | – | 1.91% | 16 |
|
|
2015
Q4 | $20.1M | Sell |
58,711
-318
| -0.5% | -$95.5K | 1.99% | 19 |
|
|
2015
Q3 | $15M | Buy |
59,029
+1,962
| +3% | +$561K | 2.16% | 17 |
|
|
2015
Q2 | $16M | Buy |
+57,067
| New | +$17.6M | 1.61% | 20 |
|
RA Capital Management's CDTX Position: Q1 2026 in Review
RA Capital Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 3,365,523 shares — an estimated $743M sold.
RA Capital Management first reported a position in CDTX in Q2 2015 and held it in 11 quarters. The position peaked at $743M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- RA Capital Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- RA Capital Management sold 3,365,523 Cidara Therapeutics shares in Q1 2026, an estimated $743M.
- RA Capital Management first reported a position in Cidara Therapeutics in Q2 2015 and held it in 11 quarters.
- RA Capital Management's Cidara Therapeutics position peaked at $743M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.